Money

Found 78,558 articles

• Sirona Biochem Announces Debenture Financing

  3/23/2023

  Sirona Biochem Corp. is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures.

• Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

  3/23/2023

  Today, Arch Biopartners Inc. announced that Arch is receiving advisory services and up to $4,000,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) to support the research and development of the LSALT peptide (Metablok) program.

• Nyxoah Announces a $15 Million Private Placement Financing

  3/23/2023

  Nyxoah SA announced a €13.35 million private placement financing from the sale of 2,047,544 new ordinary shares at a price per share of €6.52, the closing price on Euronext Brussels on March 23, 2023.

• LUNGevity Announces Pierre Massion Young Investigator Awards for Early Detection Research

  3/23/2023

  LUNGevity Foundation is honored to announce the recipients of the Pierre Massion Young Investigator Award for Lung Cancer Early Detection Research.

• Aptose Reports Results for the Fourth Quarter and Full Year 2022

  3/23/2023

  Aptose Biosciences Inc. announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

• IntelGenx to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 – Conference Call to Follow

  3/23/2023

  IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that it will release its fourth quarter and full year 2022 financial results after market close on Thursday, March 30, 2023.

• Harrow Announces Fourth Quarter and Year-End 2022 Financial Results

  3/23/2023

  Harrow, a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2022.

• Medtronic Announces Pricing of $2.0 Billion of Senior Notes

  3/23/2023

  Medtronic plc announced that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A., has priced an offering of $1,000,000,000 principal amount of 4.25% senior notes due 2028 and $1,000,000,000 principal amount of 4.50% senior notes due 2033.

• Nordic Nanovector - Annual and Remuneration Reports Approved

  3/23/2023

  On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2022.

• PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

  3/23/2023

  PureTech Health plc and Royalty Pharma announced that Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT for up to $500 million, with $100 million in cash up front and up to $400 million in additional payments contingent on the achievement of certain regulatory and commercial milestones.

• NovaBay Pharmaceuticals to Hold 2022 Fourth Quarter and Full Year Conference Call on March 30, 2023

  3/23/2023

  NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

• Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update

  3/23/2023

  POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its results for the year ended December 31, 2022 and provided a corporate update.

• Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility

  3/23/2023

  POXEL SA announced that is has finalized agreements with its lenders to restructure its existing debt obligations and a new equity-linked financing with IRIS with an initial drawdown of EUR 3.5 million.

• Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update

  3/23/2023

  Innate Pharma SA reported its consolidated financial results1 for the year ending December 31, 2022.

• Affimed Reports 2022 Financial Results and Operational Progress

  3/23/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the year ended December 31, 2022, and provided an update on clinical and corporate progress.

• Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary

  3/23/2023

  Helius Medical Technologies, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.001 per share, for each outstanding share of Helius Class A common stock held of record on April 3, 2023.

• TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

  3/23/2023

  TCR² Therapeutics Inc. announced fourth quarter and full-year 2022 financial results and provided a corporate update.

• Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results

  3/23/2023

  Applied Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

• Valneva Reports Full Year 2022 Results and Provides Corporate Updates

  3/23/2023

  Valneva SE a specialty vaccine company, reported its consolidated financial results for the year ending December 31, 20224 and provided corporate updates.

• Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023

  3/23/2023

  Atreca, Inc. announced that it will host a conference call and webcast on Wednesday, March 29, 2023, at 4:30 p.m. EDT to report financial results and provide an update on its discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101.